PERK Inhibition Mitigates Restenosis and Thrombosis: A Potential Low-Thrombogenic Antirestenotic Paradigm

Research output: Contribution to journalArticle

Authors

External Institution(s)

  • Ohio State University
  • University of Wisconsin-Madison

Details

Original languageEnglish (US)
Pages (from-to)245-263
Number of pages19
JournalJACC: Basic to Translational Science
Volume5
Issue number3
StatusPublished - Mar 2020
Peer-reviewedYes

Abstract

Developing endothelial-protective, nonthrombogenic antirestenotic treatments has been a challenge. A major hurdle to this has been the identification of a common molecular target in both smooth muscle cells and endothelial cells, inhibition of which blocks dysfunction of both cell types. The authors’ findings suggest that the PERK kinase could be such a target. Importantly, PERK inhibition mitigated both restenosis and thrombosis in preclinical models, implicating a low-thrombogenic antirestenotic paradigm.

    Research areas

  • PERK, endothelial cells, restenosis, smooth muscle cells, thrombosis

Citation formats

APA

Harvard

Wang, B, Zhang, M, Urabe, G, Huang, Y, Chen, G, Wheeler, D, Dornbos, DJ, Huttinger, A, Nimjee, SM, Gong, S, Guo, LW & Kent, KC 2020, 'PERK Inhibition Mitigates Restenosis and Thrombosis: A Potential Low-Thrombogenic Antirestenotic Paradigm', JACC: Basic to Translational Science, vol. 5, no. 3, pp. 245-263. https://doi.org/10.1016/j.jacbts.2019.12.005